PROCEPT BioRobotics Co. (NASDAQ:PRCT) Stock Position Increased by Alliancebernstein L.P.

Alliancebernstein L.P. grew its position in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 14.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,752,478 shares of the company’s stock after purchasing an additional 218,148 shares during the period. Alliancebernstein L.P.’s holdings in PROCEPT BioRobotics were worth $141,110,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PRCT. Raleigh Capital Management Inc. acquired a new stake in PROCEPT BioRobotics in the 4th quarter valued at approximately $32,000. Signaturefd LLC grew its stake in shares of PROCEPT BioRobotics by 26.7% in the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock worth $55,000 after purchasing an additional 145 shares in the last quarter. IFP Advisors Inc acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter valued at $58,000. Arcadia Investment Management Corp MI bought a new stake in shares of PROCEPT BioRobotics during the fourth quarter valued at about $64,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in PROCEPT BioRobotics in the third quarter worth about $64,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Trading Down 2.0 %

PROCEPT BioRobotics stock opened at $57.09 on Wednesday. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of -29.28 and a beta of 1.05. PROCEPT BioRobotics Co. has a 1 year low of $45.56 and a 1 year high of $103.81. The firm’s 50 day moving average price is $64.98 and its two-hundred day moving average price is $77.66. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The company had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. On average, research analysts predict that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on PRCT. Morgan Stanley lowered their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Truist Financial reissued a “buy” rating and set a $90.00 target price (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $112.00 price target on shares of PROCEPT BioRobotics in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $94.29.

Insiders Place Their Bets

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now directly owns 173,070 shares of the company’s stock, valued at $9,875,374.20. The trade was a 3.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin Waters sold 733 shares of the firm’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total value of $41,824.98. Following the completion of the sale, the chief financial officer now directly owns 107,991 shares of the company’s stock, valued at approximately $6,161,966.46. This trade represents a 0.67 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,455 shares of company stock worth $368,322. Company insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).